Elucidating signaling pathways is a fundamental step in understanding cellular processes and developing new therapeutic strategies. Here we introduce a method for the large-scale elucidation of signaling pathways involved in cellular response to drugs. Combining drug targets, drug response expression profiles, and the human physical interaction network, we infer 99 human drug response pathways and study their properties. Based on the newly inferred pathways, we develop a pathway-based drug-drug similarity measure and compare it to two common, gold standard drug-drug similarity measures. Remarkably, our measure provides better correspondence to these gold standards than similarity measures that are based on associations between drugs and known pathways, or on drug-specific gene expression profiles. It further improves the prediction of drug side effects and indications, elucidating specific response pathways that may be associated with these drug properties. Supplementary Material for this article is available at www.liebertonline.com/cmb.
Get full access to this article
View all access options for this article.
References
1.
AronsonA.R.2001. Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap program. Proc. AMIA Symp, 17–21.
2.
AtiasN., SharanR.2011. An algorithmic framework for predicting side effects of drugs. J. Comput. Biol., 18:207–218.
3.
BodenreiderO.2004. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res, 32:D267–D270.
BrombergK.D., Ma'ayanA., NevesS.R.et al.2008. Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth. Science, 320:903–909.
6.
ChatterjeeS., PalJ., BiswasN.2008. Nimesulide-induced hepatitis and toxic epidermal necrolysis. J. Postgrad Med., 54:150–151.
7.
ChenX., XuJ., HuangB.et al.2010. A sub-pathway-based approach for identifying drug response principal network. Bioinformatics, 27:649–654.
8.
ChenY., HuY., ZhouT.et al.2009. Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am. J. Pathol., 175:2676–2685.
9.
EwingR.M., ChuP., ElismaF.et al.2007. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Syst. Biol., 3:89.
10.
FishbainD.A.1985. Priapism resulting from fluphenazine hydrochloride treatment reversed by diphenhydramine. Ann. Emerg. Med., 14:600–602.
11.
FowlerM.J.2008. Microvascular and macrovascular complications of diabetes. Clin. Diabetes, 26:77.
12.
GottliebA., SteinG.Y., RuppinE.et al.2011. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol., 7:496.
13.
HamoshA., ScottA.F., AmbergerJ.et al.2002. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res., 30:52–55.
14.
HodgkinsonC.P., SaleG.J.2002. Regulation of both PDK1 and the phosphorylation of PKC-zeta and -delta by a C-terminal PRK2 fragment. Biochemistry, 41:561–569.
15.
HuangD.W., ShermanB.T., LempickiR.A.2009. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res., 37:1.
16.
HuangR., WallqvistA., ThankiN.et al.2005. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action. Pharmacogenomics J., 5:381–399.
JaccardP.1908. Nouvelles recherches sur la distribution florale. Bul. Soc. Vaudoise Sci. Nat., 44:223–270.
19.
JiangC., XuanZ., ZhaoF.et al.2007. TRED: a transcriptional regulatory element database, new entries and other development. Nucleic Acids Res., 35:D137–D140.
20.
KanehisaM., GotoS.2000. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res., 28:27–30.
21.
KanehisaM., GotoS., FurumichiM.et al.2010. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res., 38:D355–D360.
22.
KihlB., BrattC.G., KnutssonU.et al.1980. Priapsim: evaluation of treatment with special reference to saphenocavernous shunting in 26 patients. Scand. J. Urol. Nephrol., 14:1–5.
23.
KleinT.E., ChangJ.T., ChoM.K.et al.2001. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J., 1:167–170.
24.
KuhnM., CampillosM., LetunicI.et al.2010. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol., 6:343.
25.
LambJ.2007. The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer, 7:54–60.
26.
LiuY., HuB., FuC.et al.2010. DCDB: Drug Combination Database. Bioinformatics, 26:587–588.
27.
MatterH.1997. Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors. J. Med. Chem., 40:1219–1229.
28.
MatthewsL., GopinathG., GillespieM.et al.2009. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res., 37:D619–D622.
29.
MockenhauptM., ViboudC., DunantA.et al.2007. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol., 128:35–44.
30.
NishimuraD.2001. A view from the web: BioCarta. Biotech Software Internet Rep., 2:117–120.
31.
RoujeauJ.C., KellyJ.P., NaldiL.et al.1995. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med., 333:1600–1607.
32.
RualJ.F., VenkatesanK., HaoT.et al.2005. Towards a proteome-scale map of the human protein-protein interaction network. Nature, 437:1173–1178.
33.
SaladoJ., BlazquezA., Diaz-SimonR.et al.2002. Priapism associated with zuclopenthixol. Ann. Pharmacother., 36:1016–1018.
34.
SaoudiN., BozioA., KirkorianG.et al.1991. Prolonged QT, atrioventricular block, and sudden death in the newborn: an electrophysiologic evaluation. Eur. Heart. J., 12:838–841.
35.
SharanR., SuthramS., KelleyR.M.et al.2005. Conserved patterns of protein interaction in multiple species. Proc. Natl. Acad. Sci. USA, 102:1974.
36.
SkrboA., BegovicB., SkrboS.2004. [Classification of drugs using the ATC system (Anatomic, Therapeutic, Chemical Classification) and the latest changes]Med. Arh., 58:138–141.
37.
SteinbeckC., HoppeC., KuhnS.et al.2006. Recent developments of the chemistry development kit (CDK)—an open-source Java library for chemo- and bioinformatics. Curr. Pharm. Des., 12:2111–2120.
38.
StelzlU., WormU., LalowskiM.et al.2005. A human protein-protein interaction network: a resource for annotating the proteome. Cell, 122:957–968.
39.
StudentZ.1908a. The probable error of a mean. Biometrica, 6:1–25.
UedaK., ValdiviaC., Medeiros-DomingoA.et al.2008. Syntrophin mutation associated with long QT syndrome through activation of the nNOS–SCN5A macromolecular complex. Proc. Natl. Acad. Sci. USA, 105:9355.
42.
Van HemertA.M., MeinhardtW., MoehadjirD.et al.1995. Recurrent priapism as a side effect of zuclopenthixol decanoate. Int. Clin. Psychopharmacol., 10:199.
43.
van VeenT.A., SteinM., RoyerA.et al.2005. Impaired impulse propagation in Scn5a-knockout mice: combined contribution of excitability, connexin expression, and tissue architecture in relation to aging. Circulation, 112:1927–1935.
44.
WeiningerD.1988. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci., 28:31–36.
45.
WexlerP.2001. TOXNET: an evolving web resource for toxicology and environmental health information. Toxicology, 157:3–10.
46.
WishartD.S., KnoxC., GuoA.C.et al.2008. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res, 36:D901–906.
47.
XenariosI., SalwinskiL., DuanX.J.et al.2002. DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein interactions. Nucleic Acids Res., 30:303–305.
48.
YeangC.H., IdekerT., JaakkolaT.2004. Physical network models. J. Comput. Biol., 11:243–262.
49.
Yeger-LotemE., RivaL., SuL.J.et al.2009. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat. Genet., 41:316–323.
50.
YosefN., UngarL., ZalckvarE.et al.2009. Toward accurate reconstruction of functional protein networks. Mol. Syst. Biol., 5:248.
51.
YuanS.Y., UstinovaE.E., WuM.H.et al.2000. Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes. Circ. Res., 87:412–417.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
